Home › Companies › RLMD

Relmada Therapeutics

RLMD Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Metabolic Oncology Small Molecule

Most recent annual filing: 2026-03-19

Pipeline (4 active programs)

NDV-01

Non-Muscle-Invasive Bladder Cancer Phase 2 intravesical Trigone Pharma

sepranolone

Small Molecule Target: GABAA receptor alpha-2, GABAA receptor alpha-4

Prader-Willi Syndrome Phase 2 subcutaneous
Tourette Syndrome Phase 2 subcutaneous
Essential Tremor Phase 2

Discontinued (2)

esmethadone — Major Depressive Disorder · Program terminated effective July 7, 2025 following interim futility analysis in Phase 3 Reliance II study
psilocybin — undisclosed · Program terminated effective May 12, 2025

Biotech Distilled coverage (1)

2026-06-23 Relmada Therapeutics (RLMD) — Scientific Deep Dive for NDV-01 and Sepranolone

Articles open on Substack. Some deep dives are subscriber-only.